Golden, Colorado, Friday, April 3, 2020 3:00pm MDT – Reven, LLC, a biopharmaceutical company that is developing its flagship product Rejuveinix (RJX) for patients with vascular and metabolic related health conditions, announced today that it has submitted a proposal to … Read More
A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants. Click here for the full study details
Reven successfully completes Phase I clinical trials and is pleased to announce completion with no Serious Adverse Events and no Unexpected Adverse Events. Results are expected to be submitted to the FDA during the next few weeks.
Reven announces Phase II Clinical Development plans for upcoming human efficacy trials. These trials include exploring efficacy as an adjunct therapy for patients suffering Critical Limb Ischemia. Additional areas of focus in separate trials will be for chronic wound healing … Read More
Kevin McGovern Joins Reven’s Board of Directors. Reven announces Kevin McGovern as the newest addition to its Board of Directors. Kevin McGovern Press Release
Reven Hires Dr. James Carlson. Dr. James Carlson hired as Reven’s Executive Vice President of Development Dr. James Carlson Press Release here: Reven Press Release – 011719
MAD Cohort 3 completed dosing on January 15, 2019.
Reven Hires Susan Moore. Susan Moore hired as Reven’s Senior Director of Regulatory and Clinical Affairs.
MAD Cohort 3 begins seven-day dosing period.
Reven Hires Natalie Pizzimenti. Natalie Pizzimenti hired as Reven’s Clinical Research Scientist.
MAD Cohort 2 completed dosing on December 18, 2018.
MAD Cohort 2 begins seven-day dosing period.
SAD Cohort 6C doses subjects; SAD Cohort 6 is completed.